Dear Hair Restoration Physician and Associates,
Based on feedback from last week’s email, I have edited the biphasic-dose-response graphic below to make it more readable; please see below.

Michael Rabin, MD

(from Photomed Optics Lab) 
Biphasic photomed treatment dose-responses have been previously demonstrated (e.g., lllt in traumatic brain injury; hamblin et al).  In photomed for hair regrowth, the biphasic dose-response was thought to peak at around 4J/cm2 (similar to what had been previously described with photomed for wound healing). However, new research in photomed-induced proliferation of human dermal papilla cells shows in-vitro peak at 10J/cm2  (and with light-blocking effects of hair and skin, an in-vivo equivalent may be in the 20J/cm2 range or more).  In light of this new information, here’s where some common photomed devices for hair regrowth may lie on the revised dose-response curve:
(from PRP Cell Lab)
Below are hematology and microscopic reviews of sample PRP preparations at 2x, 6x and 10x platelet concentrations.

Please see additional information for both photomed optics lab and prp cell lab at .  And please take our PRP-Preferences Survey (part of our ‘prp+photomed for hair regrowth’ registry trial planning).
Michael Rabin, MD, MBA, CEO
LaserCap Company 
26 Alpha Park 
Highland Heights, OH 44143 
+1 440-241-1846 
About LaserCap® Company – Transdermal Cap, Inc. was formed in 2006 by co-inventors Michael Rabin, MD and M.I.T.-trained optical physicist David Smith, PhD, in collaboration with Harvard-based photomedicine expert Michael Hamblin, PhD and internationally acclaimed hair restoration physician Robert Haber, MD, to develop innovative light-based devices for the Global Beauty & Health Industries. Its first commercial product is LaserCap for women with thinning hair or at risk for thinning hair, a condition that affects up to 50% of adult women. Patents pending, Copyright 2009 Transdermal Cap, Inc.